Halozyme Therapeutics Inc. (0J2O)
LSE
Closed
Sep 24, 2026
Day's Range
111.3052 wk Range
59.85Overview - 0J2O - Halozyme Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
14.85B
P/E (Trailing)
‪0.38‬
Price / Book
‪90.56‬
EV / EBITDA
‪14.13‬
Profitability
Profit Margin
‪24.85%‬
Operating Margin
‪59.80%‬
Return on Assets
‪25.49%‬
Return on Equity
‪173.67%‬
Ownership
Shares Outstanding
143.94M
Float
112.18M
Held by Insiders
‪1.10%‬
Held by Institutions
‪112.13%‬
Price stats
Beta
‪0.88‬
50-Day Avg
‪36.88‬
200-Day Avg
‪37.43‬
Market Cap - 0J2O - Halozyme Therapeutics Inc.
Peers - 0J2O - Halozyme Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0J2OLSEHalozyme Therapeutics Inc.16.38BMarket Cap+35.66%52-week change0.38P/E (Trailing)‪24.85%‬Profit Margin
- 0MGBLSEGenmab A/S198.39BMarket Cap+15.12%52-week change33.69P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock128.96BMarket Cap+20.00%52-week change0.53P/E (Trailing)‪34.99%‬Profit Margin
- 0A45LSEModerna Inc.95.05BMarket Cap+87.31%52-week change72.95P/E (Trailing)‪11.32%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.79.08BMarket Cap+20.99%52-week change0.11P/E (Trailing)‪27.86%‬Profit Margin
- 0QW0LSEargenx SE49.68BMarket Cap+27.60%52-week change40.07P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA41.70BMarket Cap-23.88%52-week change120.47P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0J2O - Halozyme Therapeutics Inc.
About
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
